Vascular Control of NASH Progression

This project aims to characterize the gut-liver vasculature in NASH progression using spatial sorting and imaging to identify therapeutic targets and prognostic markers for HCC.

Subsidie
€ 1.741.250
2024

Projectdetails

Introduction

Non-alcoholic steato-hepatitis (NASH) is a major risk factor for hepatocellular carcinoma (HCC), the 6th most common cause of cancer-related death worldwide. The transition among different NASH stages to HCC stems from the complex interaction of multiple factors, including gut-liver axis modifications and a progressive dis-architecture of the liver parenchyma.

Endothelial Cells and NASH Progression

The central role of endothelial cells in regulating the metabolic crosstalk along the gut-liver axis and in shaping the spatial organization of the liver parenchyma suggests a potential vascular control of NASH progression. However, the possibility to precisely define the endothelial contribution is restrained by the limited ability to correlate gene expression profiling and functional readout, such as protein phosphorylation, with the complex morphological modifications occurring during NASH.

Methodology

To overcome these limitations, we combined innovative “spatial sorting” strategies with transcriptomics and quantitative phosphoproteomics, providing the first draft of the anatomical organization of proteins signaling in the liver vasculature. Moreover, we unambiguously identified tyrosine phosphorylation – the main target of the anti-angiogenic therapy (ATT) – as one of the most spatially regulated signaling events.

Research Aims

Building on this expertise, we will combine spatial sorting strategies in gut and liver with mouse models of NASH progression and advanced imaging modalities to pursue the following aims:

  1. Provide a spatiotemporal characterization of the gut and liver vasculature undergoing NASH development.
  2. Dissect the vascular determinants of NASH progression.
  3. Identify the molecular mechanisms underlying the synergistic effect between AAT and immune checkpoint inhibition.

Conclusion

Together, our results will lay the foundation for understanding the molecular basis of a synergistic AAT and immune therapy in HCC, and help to identify novel prognostic markers as well as potential therapeutic targets.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.741.250
Totale projectbegroting€ 1.741.250

Tijdlijn

Startdatum1-10-2024
Einddatum30-9-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • UNIVERSITA VITA-SALUTE SAN RAFFAELEpenvoerder

Land(en)

Italy

Vergelijkbare projecten binnen European Research Council

ERC Proof of...

Validation of a new drug target in non-alcoholic steatohepatitis

This project aims to explore oxidative stress's role in non-alcoholic steatohepatitis (NASH) and develop new treatments by targeting MAP kinases p38 and JNK.

€ 150.000
ERC Proof of...

A novel NASH model for target and drug candidate identification

The SPHERO-NASH project aims to develop a 3D liver model for studying NASH mechanisms and drug discovery, facilitating commercialization of novel therapeutic targets and compounds.

€ 150.000
ERC Starting...

Understanding Metabolic Activation of Dendritic Cells in Non-Alcoholic Fatty Liver Disease

This project aims to investigate the role of conventional dendritic cells in non-alcoholic steatohepatitis by exploring their immuno-metabolic functions and interactions with liver metabolism.

€ 2.406.250
ERC Consolid...

Scalable target identification for metabolic liver disease

The 3DMASH project aims to identify novel pharmacological targets for metabolic dysfunction-associated steatohepatitis by mapping tissue interactions using patient-derived organotypic cultures.

€ 1.950.000
ERC Proof of...

Generating mRNA-HNF4a-Lipid nanoparticles for curing pancreatic cancer-associated cachexia (CAC) in identified patients at risk

This project aims to develop and test liver-specific mRNA therapies targeting HNF4a to prevent or alleviate cancer-associated cachexia in pancreatic cancer patients identified by a novel liver score.

€ 150.000